Bedrijfsoverzicht
Impact BioMedical Inc. is a biotechnology enterprise dedicated to the discovery, development, and commercialization of products and technologies designed to address unmet needs within human healthcare and wellness sectors. The company specifically focuses on specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products within the United States market. It operates within the broader healthcare sector, specifically classified under the biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles rather than immediate revenue generation from mature products. The company currently maintains a market capitalization of $74.16M and reports an annual revenue of $32,000 over the trailing twelve months, employing a workforce of only two individuals. These financial figures indicate that the company is in a very early stage of development with minimal commercial scale, where the vast majority of its valuation is derived from potential future asset value rather than current operational cash flows or profitability.
Financiële gezondheid
Over the trailing twelve months, the company generated revenue of $32,000 while reporting a net income of -$11,838,000 and an EBITDA of -$3,125,000. The significant disparity between the minimal revenue of $32,000 and the substantial net loss of -$11,838,000 reveals a cost structure dominated by high fixed costs, likely related to research and development expenses, that far exceed current sales generation. The company recorded a free cash flow of -$1,520,375, which indicates a continuous consumption of cash reserves to fund operations and development activities, suggesting limited financial flexibility in the short term. Three distinct margin metrics illustrate the financial reality: a gross margin of 0.0%, an operating margin of -16542.9%, and a profit margin of 0.0%. The negative operating margin of -16542.9% specifically highlights that operating expenses are disproportionately high relative to the tiny revenue base, while the 0.0% gross and profit margins confirm that the company has not yet achieved operational profitability or cost recovery on its sales. In terms of solvency, the company holds $3,000 in cash against $0 in debt, resulting in a debt-to-equity ratio that is effectively N/A due to the lack of equity capitalization relative to debt obligations. This balance sheet configuration represents a highly leveraged position in a traditional sense, as the firm relies entirely on equity rather than debt financing, yet faces a severe liquidity constraint. The current ratio stands at 0.35, indicating that current assets are significantly lower than current liabilities, which points to potential short-term liquidity challenges in meeting immediate obligations. Return on Equity is recorded at -104.2% and Return on Assets at -14.2%, metrics that reveal that management has not yet been effective in generating positive returns on the capital employed or the asset base, reflecting the typical burn-rate characteristics of a pre-revenue biotechnology entity.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio and forward P/E ratio are both N/A, which implies that standard earnings-based valuation models are not applicable given the absence of positive earnings and the undefined trajectory of future profitability. The price-to-book ratio is 5.68, indicating that the market values the company at a significant premium over its net asset book value, a common phenomenon for biotechnology firms where intangible assets and future pipeline potential are priced in rather than historical book value. Alternative valuation metrics provide further context: the price-to-sales ratio is an exceptionally high 2317.48, while the EV/EBITDA stands at -24.67, suggesting that the market is pricing the stock based on speculative growth expectations rather than current cash generation capabilities or sales multiples. The stock trades within a 52-week range defined by a high of $1.95 and a low of $0.36, meaning the current price sits at a specific point relative to this historical volatility band. The beta value is listed as N/A, which means that the company's price volatility relative to the broader market cannot be quantified using standard beta coefficients, often seen in small-cap stocks with low trading volumes. The extreme price-to-sales ratio of 2317.48 combined with a negative EV/EBITDA of -24.67 suggests that investors are willing to pay a substantial multiple for potential future upside, despite the lack of current earnings power or established market position.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both N/A, indicating that there is no comparable historical data available to determine if earnings are growing faster or slower than revenue, as the company likely has limited or no prior reporting periods with significant activity. As the company does not pay a dividend, the dividend yield and payout ratio are both N/A or 0.0%, respectively, which implies that all available resources are being retained within the organization rather than distributed to shareholders. Consequently, the company must reinvest all earnings and cash reserves directly into research, development, and operational expansion to fuel future growth rather than providing income to investors. The overall growth and income profile is characterized by a total absence of historical growth metrics and a complete lack of dividend income, reflecting the strategic choice of a pre-profitability biotechnology firm to prioritize capital expenditure over shareholder returns.